Market Overview

Acorda Therapeutics Announces Positive AMPYRA Phase 2 Data in People with Post-Stroke Deficits

Share:
Related ACOR
34 Biggest Movers From Friday
28 Stocks Moving In Friday's Mid-Day Session
U.S. Biotech/Pharma Sector Daily Observations Letter: January 22, 2018 (Seeking Alpha)

Acorda Therapeutics (NASDAQ: ACOR)
today announced that a proof-of-concept trial found dalfampridine
extended release (ER) tablets, marketed as AMPYRA®
(dalfampridine) Extended Release Tablets,…
Acorda Therapeutics (NSDAQ: ACOR)
today announced that a proof-of-concept trial found dalfampridine
extended release (ER) tablets, marketed as AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg, improved walking in
people with post-stroke deficits. Post-stroke deficits refer to chronic
neurological deficits, such as impaired walking, motor and sensory
function and manual dexterity that persist in people who have had a
stroke.

“There were clear efficacy signals in the dalfampridine-ER post-stroke
deficits trial and we therefore plan to proceed with a clinical
development program for this indication. A top-line analysis of the data
found dalfampridine-ER improved walking for people with mobility
impairment resulting from ischemic stroke. Dalfampridine-ER treatment

See full press release

Posted-In: News Guidance Contracts Asset Sales M&A Global

 

Related Articles (ACOR)

View Comments and Join the Discussion!